Dr. Nelson is Vice President of Business and Science Development at Echelon Biosciences and Frontier Scientific, Inc, and is an authority on the design and synthesis of antibiotics and inventor of Nuzyra^R and Seysara^R, recently FDA approved for severe infections and dermatological use.

He obtained his BS in Chemistry and Microbiology from Gannon University, his doctorate in Organic Medicinal Chemistry and Molecular Pharmacology from Temple University. At Tufts University School of Medicine with Dr. Stuart B. Levy they formed and built Paratek Pharmaceuticals, Inc. (PRTK) where as Senior Director of Chemistry designed, synthesized and tested novel tetracyclines against bacterial and mammalian disease states.  They were funded by GSK, Merck, Bayer and Novartis to develop Nuzyra^R, and partnered with the MMV Gates Foundation, Merck, Serono, and the Families of Spinal Muscular Atrophy studying the activity of the tetracyclines in parasitic and mammalian diseases.

Dr. Nelson has received the 2019 American Chemistry Society Heroes of Chemistry Award for his work in tetracyclines, was a Fulbright Lectureship Fellow, and is a scientific board member and Vice President of Chemistry at Neumedics.